- Home
- GBCI vs TVTX Comparison
GBCI vs TVTX Comparison
Compare GBCI & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBCI | TVTX |
|---|---|---|
| Founded | 1955 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.3B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GBCI | TVTX |
|---|---|---|
| Price | $46.83 | $65.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $54.00 | $40.62 |
| AVG Volume (30 Days) | 881.0K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | 18.45 | ★ 92.89 |
| EPS | ★ 1.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.52 | $44.76 |
| Revenue Next Year | $8.46 | $35.51 |
| P/E Ratio | $33.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.90 | $22.06 |
| 52 Week High | $54.58 | $68.03 |
Technical Indicators
Market Signals| Indicator | GBCI | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.64 | 60.45 |
| Support Level | $45.57 | $53.76 |
| Resistance Level | $50.33 | $66.24 |
| Average True Range (ATR) | 0.92 | 1.98 |
| MACD | -0.11 | -0.14 |
| Stochastic Oscillator | 24.08 | 71.85 |
Price Performance
Historical ComparisonAbout GBCI Glacier Bancorp Inc.
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services through its wholly owned bank subsidiary, Glacier Bank. The group provides a full range of banking services to individuals, small to medium-sized businesses, community organizations, and public entities from several locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, Nevada, and Texas. It offers various banking products and services, including: retail banking, business banking, real estate, commercial, agriculture, and consumer loans; and mortgage origination and loan servicing services, among others.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.